B-type natriuretic peptide as a marker of heart failure: New insights from biochemistry and clinical implications

Biomarkers in Medicine

Volumn 4, Issue 2, 2010, Pages 315-320

  Vanderheyden, Marc ^a   Vrints, Chris ^b   Verstreken, Sofie ^a   Bartunek, Jozef ^a   Beunk, Jan ^a   Goethals, Marc ^a  

^a Onze Lieve Vrouwe Ziekenhuis   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

B type natriuretic peptide; B type natriuretic peptide assay; B type natriuretic peptide physiology; B type natriuretic peptide processing; Dipeptidyl peptidase

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE[1-76]; AMINOPEPTIDASE; BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE[1-32]; BRAIN NATRIURETIC PEPTIDE[3-32]; CYCLIC GMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE; NESIRITIDE; PRO BRAIN NATRIURETIC PEPTIDE[1-108]; SITAGLIPTIN; UNCLASSIFIED DRUG;

BIOAVAILABILITY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; HEART FAILURE; HUMAN; IMMUNOASSAY; MOLECULAR WEIGHT; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 77951434914     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.5     Document Type: Review

References (35)

1. Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K: International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur. J. Heart Fail. 9, 292-299 (2007). (Pubitemid 46343710)
2. Maisel A, Mueller C, Adams K et al.: State of the art: using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail. 10, 824-839 (2008).
3. Taub PR, Daniels LB, Maisel AS: Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart Fail. Clin. 5(2), 169-175 (2009).
4. Mohammed AA, Januzzi JL Jr: Natriuretic peptide guided heart failure management. Curr. Clin. Pharmacol. 4(2), 87-94 (2009).
5. Dries DL: Relevance of molecular forms of brain natriuretic peptide for natriuretic peptide research. Hypertension 49, 971-973 (2007). (Pubitemid 351664325)
6. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr: Biology of the natriuretic peptides. Am. J. Cardiol. 101(Suppl.), 3A-8A (2008). (Pubitemid 351173927)
7. Tsutamoto T, Kanamori T, Wada A, Kinoshita M: Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J. Am. Coll. Cardiol. 20, 541-546 (1992).
8. Tsutamoto T, Wada A, Maeda K et al.: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96, 509-516 (1997). (Pubitemid 27329427)
9. Shimizu H, Masuta K, Aono K et al.: Molecular forms of human brain natriuretic peptide in plasma. Clin. Chim. Acta 316, 129-135 (2002). (Pubitemid 34028197)
10. Vanderheyden M, Bartunek J, Goethals M: Brain and other natriuretic peptides: molecular aspects. Eur. J. Heart Fail. 6, 261-268 (2004). (Pubitemid 38253044)
11. Yasue H, Yoshimura M, Sumida H et al.: Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90, 195-203 (1994). (Pubitemid 24203680)
12. Ma KK, Banas K, de Bold AJ: Determinants of inducible brain natriuretic peptide promoter activity. Regul. Pept. 128, 169-176 (2005). (Pubitemid 40544831)
13. Vanderheyden M, Goethals M, Verstreken S et al.: Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J. Am. Coll. Cardiol. 44, 2349-2354 (2004). (Pubitemid 39647609)
14. Sawada Y, Suda M, Yokoyama H et al.: Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J. Biol. Chem. 272(33), 20545-20554 (1997). (Pubitemid 27355612)
15. Wu F, Yan W, Pan J, Morser J, Wu Q: Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J. Biol. Chem. 277(19), 16900-16905 (2002). (Pubitemid 34967716)
16. Tran KL, Lu X, Lei M, Feng Q, Wu Q: Upregulation of corin gene expression in hypertrophic cardiomyocytes and failing myocardium. Am. J. Physiol. Heart Circ. Physiol. 287(4), H1625-H1631 (2004). (Pubitemid 39313267)
17. Mair J: Biochemistry of B-type natriuretic peptide - where are we now? Clin. Chem. Lab. Med. 46(11), 1507-1514 (2008).
18. Luckenbill KN, Christenson RH, Jaffe AS et al.: Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin. Chem. 54, 619-621 (2008).
19. Goetze JP: Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin. Chem. 50, 1503-1510 (2004).
20. Kone BC: Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc. Res. 51, 429-441 (2001).
21. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC: Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl Acad. Sci. USA 102, 17442-17447 (2005). (Pubitemid 41740885)
22. Niederkofler E, Kiernan U, O'Rear J et al.: Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 1, 258-264 (2008).
23. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T: Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin. Chim. Acta 334, 233-239 (2003). (Pubitemid 36836080)
24. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA: Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. Clin. Endocrinol. Metab. 76, 832-838 (1993). (Pubitemid 23110823)
25. Tateyama H, Hino J, Minamino N et al.: Concentrations and molecular forms of human brain natriuretic peptide in plasma. Biochem. Biophys. Res. Commun. 185, 760-767 (1992).
26. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS: The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch. Biochem. Biophys. 451(2), 160-166 (2006).
27. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM: Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J. Am. Coll. Cardiol. 49, 1193-1202 (2007). (Pubitemid 46400332)
28. Heublein DM, Huntley BK, Boerrigter G et al.: Immunoreactivity and guanosine 3́,5́-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 49, 1114-1119 (2007). (Pubitemid 351664304)
29. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I: Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin. Chem. 52, 82-87 (2006). (Pubitemid 43032470)
30. Lambeir AM, Durinx C, Scharpé S, De Meester I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294 (2003). (Pubitemid 36775376)
31. Drucker DJ: Dipeptidyl peptidase-4 inhibition and the treatment of Type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30, 1335-1343 (2007).
32. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr: Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R897-R901 (2007). (Pubitemid 46207745)
33. Liang F, O'Rear J, Schellenberger U et al.: Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J. Am. Coll. Cardiol. 49, 1071-1078 (2007). (Pubitemid 46349497)
34. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Arstad LK, Ameenuddin S, Burnett JC: Dipeptidyl peptidase IV inhibition with sitagliptin augments cGMP-activating and hypotensive properties of B-type natriuretic peptide. J. Card. Fail. 14, S75 (2008).
35. Ezekowitz JA, Hernandez AF, Starling RC et al.: Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). Am. Heart J. 157(2), 219-228 (2009).